Friday 23 May, 2025 04:19 PM
Site map | Locate Us | Login
   Kirloskar Inds gains after Q4 PAT climbs 95% QoQ to Rs 47 cr    Shilpa Medicare zooms as arm partners with Orion Corporation    AIA Engineering gains after Q4 PAT rises 10% QoQ to Rs 285 crore    Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets    Bharti Airtel Ltd Partly Paidup leads losers in 'A' group    Dhabriya Polywood soars as Q4 PAT jumps 32% YoY to Rs 5 crore    Devyani Intl Q4 net loss widens to Rs 15 cr    Premier Explosives Ltd leads losers in 'B' group    Premier Explosives drops after weak Q4 numbers    Greenpanel Inds Q4 PAT falls 1% YoY to Rs 29 crore    Volumes spurt at Honasa Consumer Ltd counter    BEML gains as Q4 PAT jumps 12% YoY to Rs 288 cr    Healthcare shares slide    Sun Pharma drops after Q4 PAT slides 19% YoY to Rs 2,1450 cr    Mankind Pharma Ltd slips for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Mastek Q4 PAT slides 14% QoQ to Rs 81 cr; recommends final dividend of Rs 16/sh
19-Apr-25   14:31 Hrs IST

However, revenue from operations grew by 4.12% quarter on quarter (QoQ) to Rs 905.42 crore in the quarter ended 31 March 2025.

On a year-on-year (YoY) basis, Mastek's net profit declined 11.93%, while revenue rose 16.11% in Q4 FY25.

Operating EBITDA stood at Rs 138.8 crore in the March quarter, registering a decline of 1.4% QoQ and a growth of 10.9% YoY. The operating EBITDA margin reduced to 15.3% in Q4 FY25, compared to 16.2% in Q3 FY25 and 16.0% in Q4 FY24.

In terms of dollars, the firm's revenue was $104.6 million in Q4 FY25, up 1.7% QoQ and 11.6% YoY. In constant currency terms, revenue was up by 2.9% QoQ and 12.3% YoY.

The 12-month order backlog was Rs 2,290.9 crore ($264.5 million) as of 31 March 2025, as compared to Rs 2,168.4 crore ($260.0 million) in Q4 FY24, reflecting growth of 5.6% in rupee terms and 0.3% in constant currency terms on a Y-o-Y basis, and Rs 2,138.7 crore ($249.8 million) in Q3 FY25, reflecting growth of 7.1% in rupee terms and 3.8% in constant currency terms on a Q-o-Q basis.

The total cash, cash equivalents, and fair value of mutual funds stood at Rs 622.2 crore as of 31st March 2025, as compared to Rs 497 crore as of 31st December 2024.

The company added 11 new clients in Q4 FY25. Total active clients during Q4 FY25 were 348 as compared to 351 in Q3 FY25.

As of 31st March, 2025, the company had a total of 5,058 employees, of which 3,456 employees were based offshore in India, while the rest were at various onsite locations. Employee count at the end of 31st December, 2024, was 5,260. Last twelve months attrition at 19.3% in Q4FY25 in comparison with 20.1% in Q3 FY25.

On a full-year basis, the company's consolidated net profit jumped 25.18% to Rs 375.93 crore on a 13.10% increase in revenue to Rs 3,455.23 crore in FY25 over FY24.

Umang Nahata, chief executive officer, Mastek, said, 'We are pleased to report a steady performance in Q4FY25, delivering a revenue growth of 4.1% Q-o-Q and 16.1% Y-o-Y in rupee terms. We closed FY24-25 with strong annual revenue and PAT growth of 13.1% and 20.9%, respectively, in rupee terms, driven by disciplined execution across geographies and innovation across all service lines.

We continue to enhance our Data & AI capabilities across verticals, with a focused go-to-market approach targeting Fortune 1000 clients. Our 12-month order backlog grew by 7.1% Q-o-Q, reflecting strong order book performance sustained by demand for our digital engineering, cloud, and data & AI services.

Our core business, driven by UK & Europe and Oracle in US continues to grow strongly, particularly in the healthcare and commercial sectors. The UK healthcare and secured government services continue to show strong momentum, supported by the government's 10- year modernization plan and increased investments in AI and data.

With strong cash & cash equivalents of Rs 622.2 crore in Q4 FY25, we remain committed to operational efficiency and margin improvement. While macroeconomic uncertainties persist, our sharp execution focus and deep client partnerships positions Mastek for sustainable and profitable growth in FY26 and beyond.'

Meanwhile, the company's board has recommended a final dividend of Rs 16 per equity share for the financial year ended 31 March 2025, subject to shareholders' approval at the upcoming 43rd Annual General Meeting. The dividend will be paid within 30 days of approval.

Mastek is an IT company providing enterprise digital and cloud transformation services to the government/public sector, health and life sciences, retail and financial service sectors. The company's service offering includes, application development, Oracle suite & cloud migration, digital commerce, application support & maintenance, BI & analytics, assurance & testing and agile consulting.

The scrip shed 0.27% to end at Rs 2,328.10 on Thursday, 17 April 2025.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 41048927
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited